Artiva Biotherapeutics Q2 2026: RMAT Designation, Phase 3 on Track, Cash Runway into 2029

summarizeSummary

Artiva Biotherapeutics posted Q2 2026 results with a $25.0 million net loss, but the story is the RMAT designation for AlloNK in refractory RA, compelling EULAR data, and a cash runway into 2029 that fully funds the upcoming Phase 3 trial.

check_boxKey Events · Earnings and Guidance · ARTV

• FDA RMAT Designation Granted

  AlloNK plus rituximab received Regenerative Medicine Advanced Therapy designation for refractory rheumatoid arthritis, providing expedited development and review benefits.

• Phase 3 Trial Initiation H2 2026

  A registrational randomized controlled trial of AlloNK plus rituximab vs. rituximab alone in ~150 refractory RA patients will start in the second half of 2026, with ACR50 at six months as the primary endpoint.

• EULAR 2026 Data: 71% ACR50 Response

  In the Phase 2a basket trial, 5 of 7 refractory RA patients achieved ACR50 at six months; no CRS, ICANS, or AlloNK-related serious adverse events were observed across 55 patients, supporting outpatient administration.

• Cash Runway Extended into 2029

  Cash, equivalents, and investments totaled $349.4 million as of June 30, 2026, following a ~$300 million May offering, expected to fund operations through the Phase 3 readout and into 2029.

auto_awesomeAnalysis · ARTV · Life Sciences

Artiva Biotherapeutics reported Q2 2026 results alongside transformative clinical and regulatory progress. The FDA granted RMAT designation for AlloNK in refractory RA, accelerating the path to market. EULAR data showed 71% ACR50 responses with a clean safety profile, supporting outpatient use. The company is initiating a Phase 3 registrational trial in H2 2026. With $349.4 million in cash following a $300 million May offering, the runway extends into 2029, de-risking the pivotal readout. The net loss widened to $25.0 million from $21.3 million a year ago, driven by increased R&D spending ahead of the Phase 3 launch.